Related Experiment Video
Updated: Feb 3, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
Mild Pulmonary Hypertension Is Associated With Increased Mortality: A Systematic Review and Meta-Analysis
Dhaval Kolte1,2, Suvasini Lakshmanan1, Matthew D Jankowich1,2,3
11 Providence Veterans Affairs Medical Center Warren Alpert Medical School of Brown University Providence RI.
Abstract:
Background Recent studies have demonstrated a continuum in clinical risk related to mean pulmonary artery pressure that begins at >19 mm Hg, which is below the traditional threshold used to define pulmonary hypertension ( PH ) of 25 mm Hg. Because of the implications on patient diagnosis and prognosis, the generalizability and validity of these data need further confirmation. Methods and Results Databases were searched from inception through January 31, 2018, to identify studies comparing all-cause mortality between patients with mildly elevated mean pulmonary artery pressure near but <25 mm Hg versus the referent group. The meta-analysis included 15 nonrandomized studies and 16 482 patients (7451 [45.2%] with measured or calculated mean pulmonary artery pressure of 19-24 mm Hg by right heart catheterization [n=6037] and echocardiography [n=1414] [mild PH ]). The mean duration of follow-up was 5.2 years. Compared with the referent group, mild PH was associated with an increased risk of mortality (risk ratio, 1.52; 95% confidence interval, 1.32-1.74; P<0.001; I2=47%). Secondary analysis using risk-adjusted time-to-event estimates showed a similar result (hazard ratio, 1.19; 95% confidence interval, 1.09-1.31; P<0.001; I2=42%). The findings were consistent between subgroups of right heart catheterization and echocardiography studies ( Pinteraction>0.05). There was evidence of publication bias; however, this did not influence the risk estimate (Duval and Tweedie's trim and fill adjusted risk ratio, 1.34; 95% confidence interval, 1.15-1.56). Conclusions The risk of mortality is increased in patients with mild PH , defined as measured or calculated mean pulmonary artery pressure >19 mm Hg. These data emphasize a need for diagnosing patients with mild PH with consideration to enrollment in PH clinical studies investigating pharmacological and nonpharmacological interventions to attenuate clinical risk and improve outcomes.
Insights
Mild pulmonary hypertension (PH), defined as mean pulmonary artery pressure >19 mm Hg, is linked to a significantly increased mortality risk. This finding supports earlier diagnosis and intervention for patients with mild PH to improve outcomes.
Area of Science:
- Cardiology
- Pulmonology
- Clinical Risk Assessment
Background:
- Recent studies suggest a clinical risk continuum for pulmonary artery pressure (PAP) starting above 19 mm Hg, below the traditional 25 mm Hg threshold for pulmonary hypertension (PH).
- The generalizability and validity of this lower threshold require confirmation due to its implications for patient diagnosis and prognosis.
Purpose of the Study:
- To confirm the association between mildly elevated mean PAP and all-cause mortality.
- To evaluate the risk of mortality in patients with mild PH compared to a referent group.
Main Methods:
- A meta-analysis of 15 nonrandomized studies including 16,482 patients (7451 with mild PH: 19-24 mm Hg) was conducted.
- Data were sourced from databases up to January 31, 2018, utilizing right heart catheterization and echocardiography measurements.
- Follow-up duration averaged 5.2 years.
Main Results:
- Mild PH was associated with a 52% increased risk of mortality (Risk Ratio: 1.52; 95% CI: 1.32-1.74).
- Risk-adjusted time-to-event analysis showed a similar increase (Hazard Ratio: 1.19; 95% CI: 1.09-1.31).
- Findings were consistent across measurement methods, and publication bias did not significantly alter the risk estimate.
Conclusions:
- An elevated risk of mortality exists in patients with mild PH (mean PAP >19 mm Hg).
- These findings highlight the need for diagnosing and considering mild PH patients for clinical studies on interventions to mitigate risk and enhance outcomes.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Review and Preview
Percentiles are a type of fractile that partition data into...

